Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Alexza

Alexza?uq=UG6efJS6
2000 FOUNDED
M&A STATUS
71-80 EMPLOYEES
M&A LATEST DEAL TYPE
$55M LATEST DEAL AMOUNT
Description

Developer of novel products designed to be used for the acute treatment of central nervous system conditions. The company's novel products are based on the Staccato system, a hand-held inhaler designed to deliver a drug aerosol to the deep lung, providing rapid systemic delivery and therapeutic onset in a non-invasive manner, enabling patients suffering from agitation due to schizophrenia or bipolar I disorder get faster relief.

Website
Formerly Known As
Alexza Molecular Delivery Corporation, FaxMed
Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Primary Industry
Drug Delivery
Other Industries
Pharmaceuticals
Drug Discovery
Parent Company
Grupo Ferrer
Primary Office
  • 2091 Stierlin Court
  • Mountain View, CA 94043
  • United States

+1 (650) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Alexza’s full profile, request a free trial.

Alexza Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
16. Merger/Acquisition 21-Jun-2016 $55M 00000 0000 Completed Profitable
15. PIPE 24-Feb-2016 000 00000 Completed Clinical Trials - Phase 1
14. PIPE 28-Oct-2014 0000 00000 Completed Clinical Trials - Phase 1
13. PIPE 23-Jul-2012 0000 00000 Completed Clinical Trials - Phase 1
12. 2PO 17-Feb-2012 0000 00000 Completed Clinical Trials - Phase 1
11. PIPE 26-May-2010 0000 00000 Completed Clinical Trials - Phase 1
10. Debt - General 05-May-2010 0000 00000 Completed Clinical Trials - Phase 1
9. PIPE 06-Oct-2009 000.00 00000 Completed Clinical Trials - Phase 1
8. PIPE 31-Mar-2008 $60M $229M Completed Clinical Trials - Phase 1
7. 2PO 05-Jul-2007 $18.7M $169M Completed Clinical Trials - Phase 1
To view this company’s complete deal history including valuation and funding, request access »

Alexza Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000000 0000000 26-Aug-2009 000000000000000000 000.00 Drug Discovery
To view this company’s complete investment and acquisition history, request access »

Alexza Former Investors (15)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
5AM Ventures Venture Capital Minority 000 0000 000000 0
Abingworth Management Venture Capital Minority 000 0000 000000 0
Alloy Ventures Venture Capital Minority 000 0000 000000 0
Azimuth Opportunity Investment Bank Minority 000 0000 000000 0
Bio*One Capital Corporate Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 15 investors. Get the full list »

Alexza Executive Team (18)

Name Title Board
Seat
Contact
Info
Thomas King Chief Executive Officer, President & Board Member
Tatjana Naranda Ph.D President & Chief Operating Officer
Stacy Palermini Vice President, Finance, Corporate Secretary & Treasurer
Edwin Kamemoto Ph.D Executive Vice President, Research & Development, Regulatory and Quality
Corinna Chen Senior Director, Business and Corporate Development

9 Former Executives

You’re viewing 5 of 18 executives. Get the full list »

Alexza Board Members (10)

Name Representing Role Since Contact
Info
Isaac Stein JD Alexza Lead Director 000 0000
Thomas King Alexza Chief Executive Officer, President & Board Member 000 0000

8 Former Board Members

You’re viewing 2 of 10 board members. Get the full list »